LIR Life Sciences Reports Promising Interim Preclinical Results

LIR Life Sciences Corp. has reported positive interim results from an ongoing comparative mouse study. The research focuses on cell-penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. The study's interim analysis shows that a novel semaglutide/CPP topical formulation effectively reduces blood glucose after an oral glucose challenge. This demonstrates pharmacologically meaningful activity compared to untreated controls.

The study compares a topical skin-applied CPP formulation of semaglutide against injectable semaglutide and untreated controls. The promising results suggest that the CPP-enabled topical formulation delivers active drug across the skin barrier at pharmacologically meaningful levels. This achievement is a technical milestone for LIR's platform, indicating that CPP-based systems could effectively transport large peptide drugs through the skin, achieving sustained glucose control.

LIR's interim findings offer in vivo support for its CPP-enabled transdermal platform. The company emphasizes the analytical phase's success in refining formulations, confirming dose ranges, and guiding future studies. The study's progress supports further funding for additional comparative studies using other GLP/GIP-based therapies.

Edward Mills, CEO of LIR Life Sciences, expressed optimism, noting that the CPP-enabled topical formulation shows a significant glucose-lowering effect. This discovery bolsters the company's needle-free drug delivery approach and provides a foundation for further development and studies.